VON WILLEBRAND DISEASE
-
CHS 5-year strategic framework officially launched!
The CHS is pleased to share its brand new five-year strategic framework following an extensive strategic planning exercise held in 2020. The strategy is expressed...
-
Coagulation products | Current and in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates,...
-
The World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines
April 12, 2021 — Please see the World Federation of Hemophilia/European Haemophilia Consortium statement on very rare adverse events with COVID-19 vaccines: www1.wfh.org/docs/website/en/News/WFH-EHC-Statement-on-EMA-April2021.pdf The key...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...
-
FAQs – COVID-19 vaccine and bleeding disorders
The Association of Hemophilia Clinic Directors of Canada (AHCDC) has issued a message to address the most frequent questions asked with regards to the COVID-19...